Look back at pharma news in the week to September 18, 2020

20 September 2020

By Barbara Obstoj-Cardwell. Editor

Last week saw a major M&A activity, with Gilead Sciences announcing a $21 billion deal to acquire Immunomedics and its breast cancer drug Trodelvy. On the research front, Swiss pharma giant Roche reported new real-world data on its Ocrevus, showing significant benefit in slowing multiple sclerosis disease progression. Among licensing news, Seattle Genetics signed a collaboration with Merck & Co, which could be worth $4.2 billion, and involves the cancer drugs ladiratuzumab vedotin and Tukysa. Also, US mRNA specialist Moderna entered into two collaborations, one with Italy’s Chiesi on pulmonary arterial hypertension (PAH), and the other with Vertex, expanding their existing cystic fibrosis collaboration.

Trodelvy deal requires more than TNBC to create value

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK